Biohaven Pharmaceutical Holding Stock Performance
| BHVN Stock | USD 11.48 0.12 1.06% |
On a scale of 0 to 100, Biohaven Pharmaceutical holds a performance score of 6. The firm shows a Beta (market volatility) of -0.23, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biohaven Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Biohaven Pharmaceutical is likely to outperform the market. Please check Biohaven Pharmaceutical's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Biohaven Pharmaceutical's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biohaven Pharmaceutical Holding are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Biohaven Pharmaceutical displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.06 | Five Day Return (1.88) | Year To Date Return 5.9 | Ten Year Return 57.26 | All Time Return 57.26 |
1 | Biohaven Issues Quarterly Earnings Results | 12/03/2025 |
2 | Whats Going On With Biohaven Stock Friday | 12/26/2025 |
3 | Acquisition by Antonijevic Irina of 11000 shares of Biohaven Pharmaceutical subject to Rule 16b-3 | 12/29/2025 |
4 | Biohaven Is Down 6.1 percent After Ending BHV-7000 Depression Trial To Refocus On Epilepsy And Obesity | 01/05/2026 |
5 | Biohaven Shares Up 11.9 percent Heres Why | 01/07/2026 |
6 | Biohaven Ltd. Shares Surge 3.42 percent to 12.10 Amid Positive Clinical Data - Intellectia AI | 01/14/2026 |
7 | Biohaven Shares Gap Up Should You Buy | 01/21/2026 |
8 | Acquisition by Kimberly Gentile of 3750 shares of Biohaven Pharmaceutical subject to Rule 16b-3 | 01/28/2026 |
9 | Here Are Fridays Top Wall Street Analyst Research Calls Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More | 02/06/2026 |
10 | Biohaven Stock Price Up 8.4 percent - Should You Buy - MarketBeat | 02/09/2026 |
11 | Biohaven Trading Up 8.4 percent Following Analyst Upgrade | 02/12/2026 |
| Begin Period Cash Flow | 252.1 M | |
| Total Cashflows From Investing Activities | -245 M |
Biohaven Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 963.00 in Biohaven Pharmaceutical Holding on November 20, 2025 and sell it today you would earn a total of 185.00 from holding Biohaven Pharmaceutical Holding or generate 19.21% return on investment over 90 days. Biohaven Pharmaceutical Holding is currently generating 0.4281% in daily expected returns and assumes 5.2623% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Biohaven, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biohaven Pharmaceutical Target Price Odds to finish over Current Price
The tendency of Biohaven Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 11.48 | 90 days | 11.48 | about 32.84 |
Based on a normal probability distribution, the odds of Biohaven Pharmaceutical to move above the current price in 90 days from now is about 32.84 (This Biohaven Pharmaceutical Holding probability density function shows the probability of Biohaven Stock to fall within a particular range of prices over 90 days) .
Biohaven Pharmaceutical Price Density |
| Price |
Predictive Modules for Biohaven Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biohaven Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biohaven Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biohaven Pharmaceutical Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Biohaven Pharmaceutical is not an exception. The market had few large corrections towards the Biohaven Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biohaven Pharmaceutical Holding, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biohaven Pharmaceutical within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.59 | |
β | Beta against Dow Jones | -0.23 | |
σ | Overall volatility | 1.35 | |
Ir | Information ratio | 0.1 |
Biohaven Pharmaceutical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biohaven Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biohaven Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Biohaven Pharmaceutical had very high historical volatility over the last 90 days | |
| Biohaven Pharmaceutical Holding currently holds 36.58 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48. | |
| Biohaven Pharmaceutical has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Biohaven Trading Up 8.4 percent Following Analyst Upgrade |
Biohaven Pharmaceutical Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Biohaven Stock often depends not only on the future outlook of the current and potential Biohaven Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biohaven Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 91.2 M | |
| Cash And Short Term Investments | 486 M |
Biohaven Pharmaceutical Fundamentals Growth
Biohaven Stock prices reflect investors' perceptions of the future prospects and financial health of Biohaven Pharmaceutical, and Biohaven Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biohaven Stock performance.
| Return On Equity | -5.22 | ||||
| Return On Asset | -1.06 | ||||
| Current Valuation | 1.56 B | ||||
| Shares Outstanding | 132.69 M | ||||
| Price To Earning | (4.25) X | ||||
| Price To Book | 12.19 X | ||||
| EBITDA | (877.26 M) | ||||
| Net Income | (846.42 M) | ||||
| Cash And Equivalents | 23.21 M | ||||
| Cash Per Share | 8.48 X | ||||
| Total Debt | 36.58 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 0.71 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (582.45 M) | ||||
| Earnings Per Share | (7.52) X | ||||
| Market Capitalization | 1.51 B | ||||
| Total Asset | 615.11 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 384.25 M | ||||
| Current Asset | 32.52 M | ||||
| Current Liabilities | 3.61 M | ||||
About Biohaven Pharmaceutical Performance
By examining Biohaven Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Biohaven Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biohaven Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.28) | (1.34) | |
| Return On Capital Employed | (1.73) | (1.81) | |
| Return On Assets | (1.24) | (1.30) | |
| Return On Equity | (2.30) | (2.18) |
Things to note about Biohaven Pharmaceutical performance evaluation
Checking the ongoing alerts about Biohaven Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biohaven Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biohaven Pharmaceutical had very high historical volatility over the last 90 days | |
| Biohaven Pharmaceutical Holding currently holds 36.58 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48. | |
| Biohaven Pharmaceutical has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Biohaven Trading Up 8.4 percent Following Analyst Upgrade |
- Analyzing Biohaven Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biohaven Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Biohaven Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biohaven Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biohaven Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biohaven Pharmaceutical's stock. These opinions can provide insight into Biohaven Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Biotechnology sector continue expanding? Could Biohaven diversify its offerings? Factors like these will boost the valuation of Biohaven Pharmaceutical. Projected growth potential of Biohaven fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biohaven Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Biohaven Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biohaven's accounting equity. The concept of intrinsic value - what Biohaven Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biohaven Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biohaven Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biohaven Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biohaven Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.